All monotherapy | AR+ | AR− | P-Hetc | |||
---|---|---|---|---|---|---|
Individuals | Events | HR (95% CI) | HR (95% CI) | HR (95% CI) | ||
Breast cancer-free interval | ||||||
Model 1a | 1753 | 236 | 0.67 (0.52–0.87) | 0.73 (0.55–0.98) | 0.49 (0.27–0.87) | 0.22 |
p = 0.003 | p = 0.03 | p = 0.02 | ||||
Model 2b | 1697 | 227 | 0.57 (0.44–0.75) | 0.63 (0.47–0.85) | 0.39 (0.21–0.72) | 0.16 |
p < 0.001 | p = 0.003 | p = 0.002 | ||||
Disease-free survival | ||||||
Model 1 | 1753 | 401 | 0.75 (0.62–0.92) | 0.80 (0.64–0.99) | 0.61 (0.39–0.94) | 0.27 |
p = 0.005 | p = 0.04 | p = 0.03 | ||||
Model 2 | 1697 | 388 | 0.69 (0.56–0.84) | 0.73 (0.59–0.92) | 0.52 (0.33–0.83) | 0.19 |
p < 0.001 | p = 0.008 | p = 0.005 |